24 March 2025
|
2
min read
The Times profiled Genomics and its CEO, Professor Sir Peter Donnelly, highlighting the company’s work on polygenic risk scores for common diseases. The piece explores how their MHRA-approved technology could reshape preventive healthcare, and the potential for rollout across the NHS.
This feature was originally published in The Times.
